
In today’s briefing:
- S&P/ASX 200: Profit Targets After Sep-25 Rebalance Methodology Finalized
- Hybridan Research: Coro Energy Plc: Power Surge
- Telix Pharmaceuticals (TLX AU): Here’s Why Sentiment Has Improved

S&P/ASX 200: Profit Targets After Sep-25 Rebalance Methodology Finalized
- As reported by Brian Freitas , 2 days ago S&P DJI confirmed that the proposals in the market consultation will be implemented at the September 25 rebalance. Details here.
- The S&P/ASX 200 (AS51 INDEX) is currently OVERBOUGHT according to our models: the index reached an 83% probability of reversal at the intraweek high (9025). Incoming pullback.
- The index could rally one more week (next week), that should be the end of this rally (short-term forecast), but could also pull back this week, checkour modelkey-supports.
Hybridan Research: Coro Energy Plc: Power Surge
- The financial components of the regenerative funding are completed, raising a combined £1.68m via a Placing and an open WRAP Retail offer at 0.5p.
- The funding, representing 41.1% of the issued share capital, will accelerate the roll-out of the rooftop solar energy in Vietnam aiming to provide high margin, sustainable, long term cashflows from credit worthy Commercial and Industrial (C&I) customers.
- Vietnam has a clean energy agenda as it transitions away from coal and fossil fuels to produce 28-36% of its 560.4bn KW per annum power usage in renewables by 2030.
Telix Pharmaceuticals (TLX AU): Here’s Why Sentiment Has Improved
- For 1H25, Telix Pharmaceuticals (TLX AU) recorded revenue of $390M, up 63% YoY and 41% HoH. Even after excluding RLS revenue, base business revenue grew 30% YoY and 12% HoH.
- Illuccix continues to drive revenue growth. Global sales of Illuccix were $306M in 1H25, up 29% YoY, reflecting continued growth in sales volume and market share gains in the U.S.
- SEC subpoena has not affected the normal business operation. Telix is “fully cooperating with the SEC and is in the process of responding to the information request.”